Spark Therapeutics is a gene therapy company that aims to challenge the inevitability of genetic diseases by developing potentially curative, one-time gene therapy products. Their pipeline includes programs for blindness, choroideremia, hemophilia, and other retinal and hematologic disorders. With a proprietary manufacturing platform and expertise across research, clinical, regulatory, and manufacturing, Spark Therapeutics is at the forefront of innovation in gene therapy. Recently, the company was acquired by Roche for a valuation between $4.3B and $4.8B.